National Institute on Drug Abuse (NIDA)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute on Drug Abuse (NIDA) sits in the top decile of US sponsors by registered trial count (#108 of 15,742 sponsors by registered trial count).
National Institute on Drug Abuse (NIDA): 335 sponsored US clinical trials, 14 recruiting.
National Institute on Drug Abuse (NIDA) sponsors 335 registered US clinical trials on ClinicalTrials.gov, 14 of them currently recruiting, and 292 completed. 30 of these trials are in Phase 3-4 (later-stage) and 202 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cocaine-Related Disorders, with 17 trials.
Top-decile sponsor footprint
National Institute on Drug Abuse (NIDA) ranks in the top decile of sponsors by registered trial count (#108 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
292 of 316 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
335 total, page 7 of 7
Buprenorphine Detox With Two Types of Treatment. BBD I - 10
NCT00000228
Evaluation of a Desipramine Ceiling in Cocaine Abuse - 1
NCT00000245
Flupenthixol Decanoate in Methamphetamine Smoking - 1
NCT00000241
Alternate-Day Buprenorphine Administration. Phase IV - 5
NCT00000223
Alternate Day Buprenorphine Administration, Phase X - 15
NCT00000233
Alternate-Day Buprenorphine. Phase V - 6
NCT00000224
Alternate-Day Buprenorphine Administration. Phase VI - 7
NCT00000225
Buprenorphine Dosing Interval - 5
NCT00000209
The Genetic Basis for Vulnerability to Substance Abuse
NCT00247819
Alternate-Day Buprenorphine Administration. Phase II - 4
NCT00000222
Buprenorphine Maintenance for Opiate Dependence - 6
NCT00000357
Alternate-Day Buprenorphine Administration. Phase I - 3
NCT00000221
Methadone/Buprenorphine Cross-Over Study - 4
NCT00000208
Buprenorphine Detoxification With Two Types of Treatment. BBD IV - 13
NCT00000231
Gradual Vs. Rapid Buprenorphine Detoxification - 2
NCT00000220
Evaluation of L-alpha-acetylmethadol (LAAM) in Methadone Patients - 5
NCT00000356
Treatment Efficacy for Drug Abuse and AIDS Prevention - 1
NCT00000210
Treatment Efficacy for Drug Abuse and AIDS Prevention - 2
NCT00000211
Propranolol for Treatment of Cocaine Addiction - 2
NCT00000197
Pharmacological Modulation of Cocaine Effects - 1
NCT00000201
Risperidone Treatment in Dually-Diagnosed Individuals - 2
NCT00000267
Buprenorphine Pharmacology Related to Addiction Treatment - 18
NCT00000236
Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7
NCT00000358
Study Comparing Liquid and Tablet Buprenorphine Formulations - 5
NCT00000302
Effectiveness of the Nicotine Patch in Suppressing Nicotine Withdrawal Symptoms in Women Versus Men - 1
NCT00218140
Buprenorphine Pharmacology Related to Addiction Treatment - 21
NCT00000239
Psychostimulant Abuse - Novel Treatment Approaches - 1
NCT00000325
Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9
NCT00000344
IV Cocaine Abuse: A Laboratory Model - 4
NCT00000215
Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9
NCT00015275
Pharmacotherapy and Intensive Treatment - 2
NCT00000218
Alternate Day Buprenorphine Administration, Phase XII - 17
NCT00000235
Alterations in Serotonergic Functions in Cocaine Addicts - 1
NCT00000312
Early Tobacco Abstinence - 5
NCT00224965
Predictive Values of Serotonergic Alterations for Outcome - 2
NCT00000313
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 81 |
| Phase 2 | 121 |
| Phase 3 | 14 |
| Phase 4 | 16 |
What is open in the National Institute on Drug Abuse (NIDA) pipeline
14 recruiting of 335 indexed (4% open); 292 completed (87%).
Phase mix: 30 late (III/IV) vs 202 early (I/II) (early-phase heavy).
Top condition: Cocaine-Related Disorders (17 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute on Drug Abuse (NIDA): open-pipeline peers nationwide
Peers matched on 335 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
National Institute on Drug Abuse (NIDA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 335 trials (± recruiting share)
- Biogen · 334 trials · 6% recruiting
- National Institutes of Health Clinical Center (CC) · 338 trials · 7% recruiting
- Genentech · 332 trials · 7% recruiting
- Cedars-Sinai Medical Center · 339 trials · 21% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Akebia Therapeutics · 4% recruiting · 24 trials
- Dentsply Sirona Implants and Consumables · 4% recruiting · 24 trials
- Smith & Nephew · 4% recruiting · 72 trials
- Medtronic - MITG · 4% recruiting · 119 trials
Related
What to do with this National Institute on Drug Abuse (NIDA) page
335 registered trials is a research-attention snapshot, not an endorsement of National Institute on Drug Abuse (NIDA) or any single study.
- 14 of National Institute on Drug Abuse (NIDA)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cocaine-Related Disorders is the condition National Institute on Drug Abuse (NIDA) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cocaine-Related Disorders trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute on Drug Abuse (NIDA) pipeline card: 335 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.